Victory Capital Management Inc. lifted its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 403.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 18,934 shares of the company’s stock after acquiring an additional 15,176 shares during the period. Victory Capital Management Inc.’s holdings in Axsome Therapeutics were worth $1,323,000 as of its most recent filing with the SEC.
A number of other large investors have also modified their holdings of AXSM. JPMorgan Chase & Co. grew its holdings in Axsome Therapeutics by 0.5% in the 1st quarter. JPMorgan Chase & Co. now owns 176,086 shares of the company’s stock worth $7,288,000 after buying an additional 843 shares in the last quarter. Raymond James Financial Services Advisors Inc. bought a new position in shares of Axsome Therapeutics in the first quarter worth $732,000. MetLife Investment Management LLC increased its holdings in shares of Axsome Therapeutics by 59.0% during the first quarter. MetLife Investment Management LLC now owns 17,348 shares of the company’s stock valued at $718,000 after purchasing an additional 6,439 shares during the period. Panagora Asset Management Inc. bought a new stake in shares of Axsome Therapeutics during the first quarter valued at about $526,000. Finally, Sei Investments Co. lifted its holdings in Axsome Therapeutics by 1.3% in the first quarter. Sei Investments Co. now owns 146,363 shares of the company’s stock worth $6,059,000 after purchasing an additional 1,909 shares during the period. Institutional investors and hedge funds own 76.60% of the company’s stock.
Analysts Set New Price Targets
AXSM has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $180.00 price target on shares of Axsome Therapeutics in a research report on Tuesday, December 26th. Piper Sandler upped their target price on Axsome Therapeutics from $90.00 to $113.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 16th. Royal Bank of Canada initiated coverage on Axsome Therapeutics in a research report on Thursday, January 25th. They set an “outperform” rating and a $126.00 price target on the stock. Citigroup initiated coverage on Axsome Therapeutics in a report on Wednesday, December 13th. They issued a “buy” rating and a $125.00 price objective for the company. Finally, UBS Group began coverage on Axsome Therapeutics in a research note on Tuesday, February 6th. They set a “buy” rating and a $111.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $113.10.
Axsome Therapeutics Trading Up 1.3 %
Shares of NASDAQ AXSM opened at $96.89 on Monday. The business has a fifty day simple moving average of $82.41 and a 200-day simple moving average of $74.20. The company has a market cap of $4.58 billion, a price-to-earnings ratio of -21.39 and a beta of 1.21. Axsome Therapeutics, Inc. has a 12 month low of $53.71 and a 12 month high of $97.68. The company has a quick ratio of 4.38, a current ratio of 4.46 and a debt-to-equity ratio of 0.66.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
- Five stocks we like better than Axsome Therapeutics
- How to Invest in Cannabis, Step by Step
- MarketBeat Week in Review – 2/5 – 2/9
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Cloudflare results spark analysts reset: 25% upside ahead
- How to Find Cloud Software Company Stocks to Trade and Invest
- Beyond Nvidia: The hidden stars with 200% earnings growth
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.